May 26, 2022
BURLINGTON, Ontario – May 26, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, today announced that it plans to complete a private placement financing (the “Financing”) for up to $5,000,000 of gross proceeds, consisting...
May 25, 2022
BURLINGTON, Ontario – May 25, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement. The tranche consists of 506,157 Common Share...
May 12, 2022
BURLINGTON, Ontario – May 12, 2022: Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, provides the following update regarding the signing of a number of strategically significant agreements with Oakland Health Limited (operating as “RD...
April 26, 2022
BURLINGTON, Ontario – April 26, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform and Skycare Compounding Labs (“Skycare”) a leader in compounding services for the Canadian prescription market, today announce the...
March 7, 2022
BURLINGTON, Ontario – March 8, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company focused on health and wellness leveraging an innovative, proprietary oral delivery medication and nutraceutical platform, along with their UK and European partner RD Therapeutics, proudly...
February 10, 2022
BURLINGTON, Ontario – February 10, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the“Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation today announced a management change in the Company. The Board of Directors provided notice on February 9, 2022 of its intention...
January 5, 2022
BURLINGTON, Ontario – January 5, 2022- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce another significant addition to the Company’s advisory board with the appointment of Dr. Michael Glogauer. Dr....
December 22, 2021
BURLINGTON, Ontario – December 22, 2021- Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) and McMaster University (“McMaster”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final instalment of the Collaborative...
December 15, 2021
Additions to support immediate commercialization efforts for the Company’s COVID-19 vaccine candidate BURLINGTON, Ontario – December 15, 2021- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce a significant addition to...
December 9, 2021
BURLINGTON, Ontario – December 9, 2021- Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, entered into an agreement on Friday, November 26, 2021 with Oakland Health Limited (“Oakland Health” operating as “RD Therapeutics”) to...